Citations

Showing 10 of 108152 citations.

A Systematic Review of Opt‐out Versus Opt‐in Consent on Deceased Organ Donation and Transplantation (2006–2016)
Ahmad, M. Usman , Hanna, Afif, Mohamed, Ahmed‐Zayn , Schlindwein, Alex, Pley, Caitlin , Bahner, Ingrid , Mhaskar, Rahul , Pettigrew, Gavin J. , Jarmi, Tambi

Mayo Clinic

World Journal of Surgery | August 19, 2019 | Volume: 43 | Issue: 12 | Pages: 3161-3171

10.1007/s00268-019-05118-4 | PMID 31428836 Get It

AbstractBackgroundSignificant numbers of patients in the USA and UK die while waiting for solid organ transplant. Only 1–2% of deaths are eligible as donors with a fraction of the deceased donating organs. The form of consent to donation may affect the organs available. Forms of consent include: opt‐in, mandated choice, opt‐out, and organ conscription. Opt‐in and opt‐out are commonly practiced. A systematic review was conducted to determine the effect of opt‐in versus opt‐out consent on the deceased donation rate (DDR) and deceased transplantation rate (DTR).MethodsLiterature searches of PubMed and EMBASE between 2006 and 2016 were performed. Research studies were selected based on certain inclusion criteria which include USA, UK, and Spain; compare opt‐in versus opt‐out; primary data analysis; and reported DDR or DTR. Modeled effect on US transplant activity was conducted using public data from Organ Procurement and Transplantation Network and Centers for Disease Control WONDER from 2006 to 2015.ResultsA total of 2400 studies were screened and six studies were included. Four studies reported opt‐out consent increases DDR by 21–76% over 5–14 years. These studies compared 13–25 opt‐out countries versus 9–23 opt‐in countries. Three studies reported opt‐out consent increases DTR by 38–83% over 11–13 years. These studies compared 22–25 opt‐out versus 22–28 opt‐in countries. Modeled opt‐out activity on the USA resulted in 4753–17,201 additional transplants annually.ConclusionOpt‐out consent increases DDR and DTR and may be useful in decreasing deaths on the waiting list in the USA and other countries.Registration numberPROSPERO CRD42019098759.
Synergistic Genetic Interactions between Pkhd1 and Pkd1 Result in an ARPKD-Like Phenotype in Murine Models
Olson, Rory J. , Hopp, Katharina , Wells, Harrison H. , Smith, Jessica M. , Furtado, Jessica , Constans, Megan, Escobar, Diana L., Geurts, Aron M. , Torres, Vicente E. , Harris, Peter C. , Wells, Harrison, Constans, Megan M, Harris, Peter C , Torres, Vicente E

Mayo Clinic

Journal of the American Society of Nephrology | August 19, 2019 | Volume: 30 | Issue: 11 | Pages: 2113-2127

10.1681/asn.2019020150 | PMID 31427367 Get It

Significance Statement The lack of rapidly progressive murine models reflecting the more severe end of the spectrum of autosomal recessive polycystic kidney disease (ARPKD) inhibits progress to understanding ARPKD pathogenesis. Defects in primary cilia have been implicated in polycystic kidney disease, but their potential role is poorly understood. The authors generated and characterized new mouse and rat models of ARPKD and autosomal dominant polycystic kidney disease (ADPKD) and investigated the interaction between causative genes for these two conditions. Their digenic models demonstrated a synergistic interaction that better reflects the early-onset disease characteristic of ARPKD. Analysis of mRNA expression in the models highlighted different disrupted pathways, but with a commonality of dysregulated mechanisms associated with primary cilia. These models may improve understanding of ARPKD and preclinical testing for this disease. Background Autosomal recessive polycystic kidney disease (ARPKD) and autosomal dominant polycystic kidney disease (ADPKD) are genetically distinct, with ADPKD usually caused by the genes PKD1 or PKD2 (encoding polycystin-1 and polycystin-2, respectively) and ARPKD caused by PKHD1 (encoding fibrocystin/polyductin [FPC]). Primary cilia have been considered central to PKD pathogenesis due to protein localization and common cystic phenotypes in syndromic ciliopathies, but their relevance is questioned in the simple PKDs. ARPKD’s mild phenotype in murine models versus in humans has hampered investigating its pathogenesis. Methods To study the interaction between Pkhd1 and Pkd1 , including dosage effects on the phenotype, we generated digenic mouse and rat models and characterized and compared digenic, monogenic, and wild-type phenotypes. Results The genetic interaction was synergistic in both species, with digenic animals exhibiting phenotypes of rapidly progressive PKD and early lethality resembling classic ARPKD. Genetic interaction between Pkhd1 and Pkd1 depended on dosage in the digenic murine models, with no significant enhancement of the monogenic phenotype until a threshold of reduced expression at the second locus was breached. Pkhd1 loss did not alter expression, maturation, or localization of the ADPKD polycystin proteins, with no interaction detected between the ARPKD FPC protein and polycystins. RNA-seq analysis in the digenic and monogenic mouse models highlighted the ciliary compartment as a common dysregulated target, with enhanced ciliary expression and length changes in the digenic models. Conclusions These data indicate that FPC and the polycystins work independently, with separate disease-causing thresholds; however, a combined protein threshold triggers the synergistic, cystogenic response because of enhanced dysregulation of primary cilia. These insights into pathogenesis highlight possible common therapeutic targets.
Advances in neurodegenerative and psychiatric imaging: introductory editorial
Vernooij, Meike W. , Kotsenas, Amy L. , Port, John D.

Mayo Clinic

The British Journal of Radiology | August 19, 2019 | Volume: 92 | Issue: 1101 | Pages: No page available

10.1259/bjr.20199003 | PMID 31424288 Get It

Faculty Opinions recommendation of Leigh Syndrome Mouse Model Can Be Rescued by Interventions that Normalize Brain Hyperoxia, but Not HIF Activation.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | August 19, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736399107.793563797 Get It

Management of Diarrhea in Patients With Carcinoid Syndrome
Naraev, Boris G., Halland, Magnus , Halperin, Daniel M. , Purvis, Amy J., Hálfdánarson, Þorvarður R. , Halfdanarson, Thorvardur R , O’Dorisio, Thomas M.

Mayo Clinic

Pancreas | August 19, 2019 | Volume: 48 | Issue: 8 | Pages: 961-972

10.1097/mpa.0000000000001384 | PMID 31425482 Get It

Abstract Neuroendocrine tumors (NETs) arise from enterochromaffin cells found in neuroendocrine tissues, with most occurring in the gastrointestinal tract. The global incidence of NETs has increased in the past 15 years, likely due to better diagnostic methods. Small-bowel NETs are frequently associated with carcinoid syndrome (CS). Carcinoid syndrome diarrhea occurs in 80% of CS patients and poses a substantial symptomatic and economic burden. Patients with CS diarrhea frequently suffer from diarrhea and flushing and report corresponding impairment in quality of life, requiring substantial changes in daily activities and lifestyle. Treatment paradigms range from surgical debulking to liver-directed therapies to treatment with somatostatin analogs, nonspecific anti-diarrheal agents, and a tryptophan hydroxylase inhibitor. Other causes of diarrhea, including steatorrhea, short bowel syndrome, and bile acid malabsorption, should be considered in NET patients with refractory diarrhea. More therapeutic options are needed for symptomatic management of patients with NETs, and better understanding of the pathophysiology can empower clinicians with improved patient care.
Interventions for replacing missing teeth: partially absent dentition
Abt, Elliot , Worthington, Helen V , Carr, Alan B.

Mayo Clinic

Cochrane Database of Systematic Reviews | August 19, 2019 | Volume: 2019 | Issue: 7 | Pages: No page available

10.1002/14651858.cd003814.pub3 | PMID 31425605 Get It

Cardiovascular implantable electronic device infections due to enterococcal species: Clinical features, management, and outcomes
Oh, Timothy S. , Le, Katherine, Sohail, M. Rizwan , Vikram, Holenarasipur R. , Hernández‐Meneses, Marta , Prutkin, Jordan M. , Greenspon, Arnold J. , Carrillo, Roger G. , Danik, Stephen B., Naber, Christoph, Blank, Elisabeth, Tseng, Chi‐Hong , Uslan, Daniel Z. , Peacock, James E. , Greenspon, Arnold J , Peacock, James E , Vikram, Holenarasipur R. , Sohail, M Rizwan , Oh, Timothy S., Baddour, Larry M. , Miró, José María

Mayo Clinic

Pacing and Clinical Electrophysiology | August 19, 2019 | Volume: 42 | Issue: 10 | Pages: 1331-1339

10.1111/pace.13783 | PMID 31424091 Get It

AbstractBackgroundEnterococcal cardiovascular implantable electronic device (CIED) infections are not well characterized.MethodsData from the Multicenter Electrophysiologic Device Infection Cohort, a prospective study of CIED infections, were used for descriptive analysis of adults with enterococcal CIED infections.ResultsOf 433 patients, 21 (4.8%) had enterococcal CIED infection. Median age was 71 years. Twelve patients (57%) had permanent pacemakers, five (24%) implantable cardioverter defibrillators, and four (19%) biventricular devices. Median time from last procedure to infection was 570 days. CIED‐related bloodstream infections occurred in three patients (14%) and 18 (86%) had infective endocarditis (IE), 14 (78%) of which were definite by the modified Duke criteria. IE cases were classified as follows: valvular IE, four; lead IE, eight; both valve and lead IE, six. Vegetations were demonstrated by transesophageal echocardiography in 17 patients (81%). Blood cultures were positive in 19/19 patients with confirmed results. The most common antimicrobial regimen was penicillin plus an aminoglycoside (33%). Antibiotics were given for a median of 43 days. Only 14 patients (67%) underwent device removal. There was one death during the index hospitalization with four additional deaths within 6 months (overall mortality 24%). There were no relapses.ConclusionsEnterococci caused 4.8% of CIED infections in our cohort. Based on the late onset after device placement or manipulation, most infections were likely hematogenous in origin. IE was the most common infection syndrome. Only 67% of patients underwent device removal. At 6 months follow‐up, no CIED infection relapses had occurred, but overall mortality was 24%.
Transcriptomic Analysis of Cellular Pathways in Healing Flexor Tendons of Plasminogen Activator Inhibitor 1 (PAI‐1/Serpine1) Null Mice
Freeberg, M.A.T. , Easa, Anas, Lillis, Jacquelyn, Benoit, Danielle S. W. , Wijnen, André J. van , Awad, Hani A. , van Wijnen, Andre J , Awad, Hani A

Mayo Clinic

Journal of Orthopaedic Research | August 19, 2019 | Volume: 38 | Issue: 1 | Pages: 43-58

10.1002/jor.24448 | PMID 31424116 Get It

ABSTRACTInjuries to flexor tendons can be complicated by fibrotic adhesions, which severely impair the function of the hand. Plasminogen activator inhibitor 1 (PAI‐1/SERPINE1), a master suppressor of fibrinolysis and protease activity, is associated with adhesions. Here, we used next‐generation RNA sequencing (RNA‐Seq) to assess genome‐wide differences in messenger RNA expression due to PAI‐1 deficiency after zone II flexor tendon injury. We used the ingenuity pathway analysis to characterize molecular pathways and biological drivers associated with differentially expressed genes (DEG). Analysis of hundreds of overlapping and DEG in PAI‐1 knockout (KO) and wild‐type mice (C57Bl/6J) during tendon healing revealed common and distinct biological processes. Pathway analysis identified cell proliferation, survival, and senescence, as well as chronic inflammation as potential drivers of fibrotic healing and adhesions in injured tendons. Importantly, we identified the activation of PTEN signaling and the inhibition of FOXO1‐associated biological processes as unique transcriptional signatures of the healing tendon in the PAI‐1/Serpine1 KO mice. Further, transcriptomic differences due to the genetic deletion of PAI‐1 were mechanistically linked to PI3K/Akt/mTOR, PKC, and MAPK signaling cascades. These transcriptional observations provide novel insights into the biological roles of PAI‐1 in tendon healing and could identify therapeutic targets to achieve scar‐free regenerative healing of tendons. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 38:43–58, 2020
Genome‐Wide Meta‐Analysis of Blood Pressure Response to β 1 ‐Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies)
Hiltunen, Timo P. , McDonough, Caitrin W. , Rouby, Nihal El , Salvi, Erika , Wang, Zhiying , Garofalidou, Tatiana, Fyhrquist, F, Kontula, Kimmo , Glorioso, Valeria, Zaninello, Roberta, Glorioso, Nicola, Pepine, Carl J. , Munroe, Patricia B. , Turner, Stephan T., Chapman, Arlene B. , Boerwinkle, Eric , Johnson, Julie A. , Munroe, Patricia B , Singh, Sonal , Warren, Helen R. , Chapman, Arlene B. , Gong, Yan , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Journal of the American Heart Association | August 19, 2019 | Volume: 8 | Issue: 16 | Pages: No page available

10.1161/jaha.119.013115 | PMID 31423876 Get It

Background There exists a wide interindividual variability in blood pressure ( BP ) response to β 1 ‐blockers. To identify the genetic determinants of this variability, we performed a pharmacogenomic genome‐wide meta‐analysis of genetic variants influencing β 1 ‐blocker BP response. Methods and Results Genome‐wide association analysis for systolic BP and diastolic BP response to β 1 ‐blockers from 5 randomized clinical trials consisting of 1254 patients with hypertension of European ancestry were combined in meta‐analysis and single nucleotide polymorphisms (SNPs) with P <10 −4 were tested for replication in 2 independent randomized clinical trials of β 1 ‐blocker–treated patients of European ancestry (n=1552). Regions harboring the replicated SNP s were validated in a β 1 ‐blocker–treated black cohort from 2 randomized clinical trials (n=315). A missense SNP rs28404156 in BST 1 was associated with systolic BP response to β 1 ‐blockers in the discovery meta‐analysis ( P =9.33×10 −5 , β=−3.21 mm Hg) and replicated at Bonferroni significance ( P =1.85×10 −4 , β=−4.86 mm Hg) in the replication meta‐analysis with combined meta‐analysis approaching genome‐wide significance ( P =2.18×10 −7 ). This SNP in BST 1 is in linkage disequilibrium with several SNP s with putative regulatory functions in nearby genes, including CD 38 , FBXL 5 , and FGFBP 1 , all of which have been implicated in BP regulation. SNP s in this genetic region were also associated with BP response in the black cohort. Conclusions Data from randomized clinical trials of 8 European ancestry and 2 black cohorts support the assumption that BST 1 containing locus on chromosome 4 is associated with β 1 ‐blocker BP response. Given the previous associations of this region with BP , this is a strong candidate region for future functional studies and potential use in precision medicine approaches for BP management and risk prediction.
Response by Tseng et al to Letter Regarding Article, “Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis”
Mulpuru, Siva K. , Tseng, Andrew S. , Kunze, Katie L.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | August 19, 2019 | Volume: 12 | Issue: 8 | Pages: No page available

10.1161/circep.119.007710 | PMID 31422683 Get It